Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.
Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.
复制标题
甲诺加罗治疗晚期胰腺癌的 II 期试验。
DOI：
10.1097/00000421-198804000-00017
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
Hollander,P
中科院分区：
文献类型：
--
作者：
Sternberg,CN;Magill,GB;Cheng,EW;Hollander,P
15 名晚期胰腺癌患者每 3 周接受 150-225 mg/m 2 静脉注射甲诺加罗治疗。所有患者均患有二维可测量疾病。该方案和剂量方案耐受性良好，毒性（包括骨髓抑制）最小；白细胞 (WBC) 计数中位数最低值为 2,700 个细胞/mm 3 （范围为 1,400–7,100 个细胞/mm 3），血小板中位数最低值为 162,000 个细胞/mm 3 （范围为 53,000–390,000 个细胞/mm 3）。一名患者出现厌食，六名患者出现恶心或呕吐，一名患者出现静脉炎，六名患者出现脱发。没有患者做出回应。在这个剂量和时间表下，甲诺加罗在治疗晚期胰腺腺癌中没有作用。
Fifteen patients with advanced adenocarcinoma of the pancreas were treated with menogarol 150–225 mg/m 2 iv every 3 weeks. All patients had bidimensionally measurable disease. This regimen and dosage schedule are well tolerated, with minimal toxicity that included myelosupression; median white blood cell (WBC) count nadir of 2,700 cells/mm 3 (range 1,400–7,100 cells/mm 3) and median platelet nadir of 162,000 cells/mm 3 (range 53,000–390,000 cells/mm 3). Anorexia occurred in one patient, nausea or vomiting in six, phlebitis in one, and alopecia in six patients. No patients responded. At this dosage and schedule, there is no role for menogarol in the treatment of advanced pancreatic adenocarcinoma.